The Trump administration is significantly building the portfolio of drugs available through its direct-to-consumer platform TrumpRx, adding more than 600 generic medicines. President Donald Trump on Monday touted the increase as …
Another Paragon offshoot chooses reverse merger, this time for migraine drugs
They say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers. The hub-and-spoke biologics company is moving its migraine drug offshoot, Mentari Therapeutics, onto the public markets through a takeover …
Acceleron leaders and Westlake jumpstart new IPF biotech
After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million Series A round, all from Westlake …
The state of consumer health
On Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in collaboration with Endpoints News. The sessions focused on …
Q&A: Novo research chief Petersen says streamlined R&D speeds discovery
Just as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early …
OpenBind unveils its first AI model for drug discovery
A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Wave aims for monthly dosing with RNA editing treatment for AATD
Wave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. People …
Full-Life Technologies raises $150M; Quince’s reboot with pulmonary drug
Plus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised $110 million in a Series D round and another $40 …
Looking Back, Looking Forward: Digesting a Dynamic Bouillabaisse of Cyber Evolution
Dark Reading editors reflect on two decades of dramatic change — from perimeter defense to assume-breach strategies — and warn that while AI, cloud, and COVID-19 have transformed the threat landscape, organizations are still failing at fundamental security hygiene that could stop sophisticated attacks in their tracks.
Jury finds Takeda liable for $885m in pay-for-delay lawsuit
Takeda is on the hook for $885m damages – which could rise to $2.5bn – in a suit claiming it paid a rival to delay the launch of a generic competitor.
Nourish raises $100M for virtual nutrition care
***embargoed for 8am ET tomorrow tues 5/19*** Nourish, a telehealth platform that arranges virtual appointments with nutritionists, just raised a new round that bumped its valuation to $1.75 billion, according to a person familiar with …
Colossal Biosciences is growing chickens in a 3D-printed container
The baby chicks were shifting and starting to pip—or trying to hatch. But not from an egg. Instead, these chickens were growing inside transparent 3D-printed plastic cups at the Dallas headquarters of Colossal Biosciences. The biotech company today claimed it has developed a “fully artificial egg” as part of its effort to resurrect extinct avian […]